s6y

GT Biopharma, Inc.

Ticker
GTBP
CIK
109657
Industry
Pharmaceutical Preparations
Formerly
GT Biopharma, Inc., OXIS INTERNATIONAL INC

Financials 132

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-Q/A Quarterly Report for period ending Jun 30, 2025
  5. 10-Q/A Quarterly Report for period ending Sep 30, 2025
  6. 10-K Annual Report for period ending Dec 31, 2025
  7. 10-Q Quarterly Report for period ending Sep 30, 2025
  8. 10-Q Quarterly Report for period ending Jun 30, 2025
  9. 10-Q Quarterly Report for period ending Mar 31, 2025
  10. 10-K/A Annual Report for period ending Dec 31, 2024

All 132 financials filings

News 231

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 231 news filings

Ownership 212

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 212 ownership filings

Prospectus 111

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-1 General form of registration statement for all companies including face-amount certificate companies
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. S-1 General form of registration statement for all companies including face-amount certificate companies
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. S-1 General form of registration statement for all companies including face-amount certificate companies
  10. 424B3 Prospectus filed pursuant to Rule 424(b)(3)

All 111 prospectus filings

Proxies 55

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DEF 14A Definitive proxy statements

All 55 proxies filings

Other 144

  1. EFFECT Notice of Effectiveness
  2. D Exempt (Private) Offering
  3. SCHEDULE 13G
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. UPLOAD Letter (PDF)
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. EFFECT Notice of Effectiveness

All 144 other filings